Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial-Reference-Cited by-同舟云学术

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

Published:2013-05 Issue:6 Volume:14 Page:490-499
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Lordick Florian,Kang Yoon-Koo,Chung Hyun-Cheol,Salman Pamela,Oh Sang Cheul,Bodoky György,Kurteva Galina,Volovat Constantin,Moiseyenko Vladimir M,Gorbunova Vera,Park Joon Oh,Sawaki Akira,Celik Ilhan,Götte Heiko,Melezínková Helena,Moehler Markus

Publisher

Elsevier BV

Subject

Oncology

Reference40 articles.

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J Cancer,2010

2. Management of advanced gastric cancer;Price;Expert Rev Gastroenterol Hepatol,2012

3. Chemotherapy for advanced gastric cancer;Wagner;Cochrane Database Syst Rev,2010

4. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial;Koizumi;Lancet Oncol,2008

5. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial;Kang;Ann Oncol,2009

Cited by 729 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics;Targeted Oncology;2024-09-13

2. A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group;Japanese Journal of Clinical Oncology;2024-08-24

3. Advances in Personalized Oncology;Cancers;2024-08-16

4. Comprehensive landscape of gastric cancer-targeted therapy and identification of CSNK2A1 as a potential target;Heliyon;2024-08

5. Effect of cetuximab plus FOLFOX4 regimen on clinical outcomes in advanced gastric carcinoma patients receiving evidence-based care;World Journal of Clinical Cases;2024-06-26